NewsBenzingaGSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma Benzinga 2026.10.26 15:34 (GMT+0) Open on Benzinga Other news Stifel Maintains Hold on Home Depot, Lowers Price Target to $322 Maxim Group Initiates Coverage On Prenetics Global with Buy Rating, Announces Price Target of $41 Rogers Communications Poised To Benefit From Capex Reset, Sports Monetization These Analysts Revise Their Forecasts On First Hawaiian Following Q3 Results Ladenburg Thalmann Initiates Coverage On Nutex Health with Buy Rating, Announces Price Target of $336 Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study
Ladenburg Thalmann Initiates Coverage On Nutex Health with Buy Rating, Announces Price Target of $336
